Larimar Therapeutics, Inc. (LRMR)
NGM · Healthcare · Biotechnology
$3.63
-5.22%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$377.1M
Shares Outstanding
103.9M
Exchange
NGM
Currency
USD
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.8M | -49.5M | -64.0M | -31.1M |
| Net Income | -26.2M | -47.7M | -62.5M | -29.6M |
| Diluted EPS | $-0.41 | $-0.61 | $-0.73 | $-0.31 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -36.5M | -41.8M | -90.9M | -172.5M |
| Net Income | -35.4M | -36.9M | -80.6M | -165.7M |
| Diluted EPS | $-1.37 | $-0.84 | $-1.32 | $-2.27 |